GAINESVILLE, Fla.--(BUSINESS WIRE)--Exactech (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, announced that the first surgeries using the new Alteon® HA Femoral Hip Stem took place last week. The total hip replacements were performed by implant design team members Joseph Locker, MD, of The Orthopaedic Institute in Ocala, Fla. and Sam Sydney, MD, of Orthopaedic Associates of Central Maryland in Baltimore. This marks Exactech’s fourth orthopaedic innovation in a week to debut in U.S. operating rooms.
Locker implanted the Alteon HA Stem using a direct anterior approach. “It had the feel and ease of insertion of a proximal wedge, but with the stability of a tri-taper fully coated hydroxyapatite stem,” he said. Sydney shared his satisfaction with the “well engineered instruments and excellent feel of the implant upon final seating.”
The fully hydroxyapatite (HA) coated prosthesis, with its incremental stem sizing and proportional neck lengths, features design and surgical technique principles based on more than 25 years of clinical success.1 The HA Femoral Stem is designed to provide initial stability and long-term biologic fixation while providing surgeons a simple, broach-only system that offers flexibility to accommodate various surgical approaches.
The HA Femoral Stem is the latest addition to the Alteon product family which also includes the Tapered Wedge Femoral Stem, Neck Preserving Stem and newly released Monobloc Revision Stem. Each of the Alteon stems uses the same core femoral instruments, therefore improving O.R. efficiency.
“Exactech is coming off a phenomenal week of first surgeries, with the Alteon HA Stem being one of four new products to make its clinical debut. The HA Stem enhances Exactech’s robust portfolio of hip products by providing surgeons additional options for creating stable and reproducible femoral reconstructions,” said Edmund Loftus, Director of Engineering and Development and Hip Business Unit leader. “This past week speaks to the caliber of our surgeon and engineering design teams at Exactech, as well as everyone who works to make these surgeries happen.”
In each of these cases, the HA Femoral Stem was coupled with the InteGrip® Cup, an acetabular shell comprised of three-dimensional, porous ingrowth material, that was developed to improve initial stability and long-term fixation of the acetabular prosthesis.
Full U.S. market availability for the Alteon HA Stem is planned for the beginning of 2018.
1 Vidalain JP. Twenty-year results of the cementless Corail stem. Int Orthop. 2011 Feb;35(2):189-94.
About Exactech
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at http://www.exac.com.
A current investment profile on Exactech (Nasdaq: EXAC) is available online at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.
